SEHK:2696Biotechs
Shanghai Henlius Biotech (SEHK:2696) Advances Pipeline As Fair Value Questions Grow
Shanghai Henlius Biotech (SEHK:2696) has moved into focus after dosing the first patient in an international multicenter phase 1 trial of its nivolumab biosimilar HLX18 for multiple resected solid tumors.
See our latest analysis for Shanghai Henlius Biotech.
Despite the clinical progress, Shanghai Henlius Biotech’s share price has been under pressure in recent months, with a 30 day share price return of down 5.79% and a 90 day share price return of down 28.49%. The 3 year total shareholder...